U.S. markets close in 6 hours 26 minutes

BMO Bullish On 'Blockbuster Potential' Of Stealth BioTherapeutics' Lead Candidate

Priya Nigam

Stealth BioTherapeutics Corp (NASDAQ: MITO)'s lead drug elamipretide has “blockbuster potential” in primary mitochondrial dysfunction, or PMM, according to BMO Capital Markets.

The Analyst

BMO Capital Markets’ Matthew Luchini initiated coverage of Stealth BioTherapeutics with an Outperform rating and $29 price target. 

The Thesis

Mitochondria, which are present in almost every cell in the body, are responsible for 90 percent of the body’s energy needs. Stealth is focused on primary mitochondrial diseases, which can be present at birth or have a later onset, Luchini said in a Tuesday note. 

The company announced solid Phase 2 data in PMM and is scheduled to report Phase 3 data by the close of 2019, the analyst said.

The ongoing trial is “relatively de-risked,” and if the results are favorable, even a single Phase 3 study could support FDA approval, Luchini said. 

PMM represents a large market opportunity of about $1.2 billion in peak sales given that there are about 190,000 patients in the U.S. and EU with no approved treatment, the analyst said. 

Stealth is expected to commence a Phase 2 trial of elamipretide in geographic atrophy in the first quarter, with a data release possible by the end of 2020.  

Price Action

Stealth BioTherapeutics shares were down 4.79 percent at $14.30 at the time of publication Tuesday. 

Related Links:

Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate

The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

Latest Ratings for MITO

Date Firm Action From To
Mar 2019 Nomura Initiates Coverage On Buy
Mar 2019 BMO Capital Initiates Coverage On Outperform

View More Analyst Ratings for MITO
View the Latest Analyst Ratings

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.